Ninguline

Ninguline is a synthetic opioid analgesic developed by the pharmaceutical company Pfizer. It is a full opioid agonist, meaning it binds to the same receptors in the brain as natural opioids like morphine, producing similar effects. Ninguline was initially developed as a potential treatment for chronic pain, but its use has been limited due to concerns about its potential for abuse and addiction. The drug is administered orally and has a relatively short half-life, which means it is quickly metabolized and eliminated from the body. Ninguline has been studied for its potential to treat various types of pain, including cancer pain, but its clinical use has been restricted due to the risks associated with opioid use. The drug is not approved for use in the United States, and its availability and use are subject to strict regulations in other countries.